0000000001236490

AUTHOR

E. De Carlo

showing 2 related works from this author

Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neur…

2020

Introduction The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management of oncological patients. The present survey reports data collected by the Italian Association for Neuroendocrine Tumors on the management of patients with neuroendocrine neoplasia (NEN) during the pandemic dissemination. Methods A survey with 57 questions was sent to NEN-dedicated Italian centers regarding the management of patients in the period March 9, 2020, to May 9, 2020 Results The main modification in the centers’ activity consisted of decreases in newly diagnosed NEN patients (− 76.8%), decreases in performed surgical procedure…

AdultMalePediatricsmedicine.medical_specialtyEndocrinology Diabetes and MetabolismAntineoplastic Agents030209 endocrinology & metabolismNeuroendocrine tumorsMedical OncologyNO03 medical and health sciencesPatient safety0302 clinical medicineEndocrinologyAmbulatory careNeuroendocrine tumorSurveys and QuestionnairesEpidemiologyPandemicHumansMedicineLS4_3PandemicsPatient Care TeamPandemicbusiness.industryCOVID-19Multidisciplinary teamContinuity of Patient Caremedicine.diseaseManagementClinical trialItalyCOVID-19; management; multidisciplinary team; neuroendocrine tumors; pandemic; peptide receptors radionuclide therapy; SARS-CoV2030220 oncology & carcinogenesisRadionuclide therapySARS-CoV2s COVID-19 SARS-CoV2 Pandemic Neuroendocrine tumors Multidisciplinary team Management Peptide receptors radionuclide therapyPeptide receptors radionuclide therapyOriginal ArticleFemaleneuroendocrine tumorsbusinessHealth care quality
researchProduct

Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement

2022

Growth hormone deficiency (GHD) describes the impairment of growth hormone (GH) secretion by the pituitary somatotroph cells. GHD may be congenital, with causes, including genetic alterations and structural brain malformations, or acquired, including midline tumours, cranial irradiation, traumatic brain injury, central nervous system infections and inflammatory conditions. GHD in children is characterised by short stature, delayed bone maturation and abnormalities in substrate metabolism, body composition, physical and psychosocial functioning, all of which improve with recombinant human GH (rhGH) therapy. The diagnosis of GHD is based on clinical signs and symptoms, biochemistry and imagin…

growth hormone deficiencySettore MED/38 - Pediatria Generale E SpecialisticaEndocrinologyage of transitionconsensusItalian Delphi consensus statementEndocrinology Diabetes and Metabolismadolescentgrowth hormone; transition; consensusgrowth hormonetransitionTransition agegrowth hormone deficiency; Transition age; adolescent
researchProduct